Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
Lung Cancer Treatment
Advertisement
HUTCHMED and GSK Partner on KRAS-EGFR Cancer Therapy
Hong Kong, Shanghai & Florham Park, New Jersey, USA, September 3, 2026 HUTCHMED (China) Limited and GSK have entered...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Advertisements
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Kelun-Biotech Reports Strong Phase II Data for Lunbotinib
CHENGDU, China, May 29, 2026 Kelun-Biotech has presented pivotal Phase II clinical trial results for its next-generation selective RET...
Nuvalent Expands Leadership in Precision Lung Cancer
CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...
Dizal Advances ZEGFROVY for EGFR Lung Cancer
SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...
FDA Approves Jazz Pharma’s Zepzelca + Tecentriq Combo for ES-SCLC
DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration...
Advertisement
